

# The involvement of aldose reductase in diabetic compli

Diabetes/metabolism Reviews

4, 323-337

DOI: 10.1002/dmr.5610040403

Citation Report

#	ARTICLE	IF	CITATIONS
1	Isolation and characterization of cDNA clones encoding aldose reductase. Current Eye Research, 1989, 8, 1021-1027.	1.5	28
2	The contributions of Jin H. Kinoshita to aldose reductase research. Experimental Eye Research, 1990, 50, 615-620.	2.6	7
3	The role of lens epithelium in sugar cataract formation. Experimental Eye Research, 1990, 50, 641-646.	2.6	58
4	Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Experimental Eye Research, 1990, 50, 355-366.	2.6	70
5	Monoaminoguanidine inhibits aldose reductase. Biochemical Pharmacology, 1991, 41, 1527-1528.	4.4	19
6	Purification, crystallization and preliminary crystallographic analysis of porcine aldose reductase. Journal of Molecular Biology, 1991, 218, 695-698.	4.2	12
7	Strategies in diabetes mellitus. Postgraduate Medicine, 1991, 89, 45-63.	2.0	5
8	Degenerated intramural pericytes (â€ghost cellsâ€™™) in the retinal capillaries of diabetic rats. Current Eye Research, 1991, 10, 339-350.	1.5	72
9	Effects of diabetes on cholinergic transmission in two rat gut preparations. Gastroenterology, 1991, 100, 123-128.	1.3	34
10	Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats. Pharmaceutical Research, 1991, 08, 1511-1515.	3.5	18
11	Glucoseâ€™induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes/metabolism Reviews, 1991, 7, 35-59.	0.3	137
12	Resolving isoforms of aldose reductase by preparative isoelectric focusing in the Rotofor. Electrophoresis, 1991, 12, 84-90.	2.4	23
13	Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats. Experientia, 1991, 47, 252-254.	1.2	11
14	Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats. Diabetologia, 1991, 34, 695-701.	6.3	48
15	Adverse Drug Effects: Part II. Annals of Pharmacotherapy, 1992, 26, 550-554.	1.9	2
17	Aldose reductase mRNA expression and its activity are induced by glucose in fetal rat aortic smooth muscle (A10) cells. Life Sciences, 1992, 51, 719-726.	4.3	19
18	Site-directed mutagenesis of His-42, His-188 and Lys-263 of human aldose reductase. Biochemical and Biophysical Research Communications, 1992, 183, 327-333.	2.1	21
19	Does sorbinil bind to the substrate binding site of aldose reductase?. Biochemical Pharmacology, 1992, 44, 2427-2429.	4.4	23

#	ARTICLE	IF	CITATIONS
20	Glucose and diabetic vascular disease 1. FASEB Journal, 1992, 6, 2905-2914.	0.5	361
21	Changes in Aldose Reductase After Crush Injury of Normal Rat Sciatic Nerve. Journal of Neurochemistry, 1992, 58, 2212-2220.	3.9	11
22	Aldose reductase: Congenial and injurious profiles of an enigmatic enzyme. Biochemical Medicine and Metabolic Biology, 1992, 48, 91-121.	0.7	143
23	Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. The Histochemical Journal, 1993, 25, 648-663.	0.6	47
24	EFFECTS OF ALDOSE REDUCTASE INHIBITION WITH EPALRESTAT ON DIABETES-INDUCED CHANGES IN RAT ISOLATED ATRIA. Clinical and Experimental Pharmacology and Physiology, 1993, 20, 207-213.	1.9	8
25	Sorbitol dehydrogenase. Full-length cDNA sequencing reveals a mRNA coding for a protein containing an additional 42 amino acids at the N-terminal end. FEBS Journal, 1993, 217, 83-87.	0.2	9
26	Crystallization and preliminary structure determination of porcine aldehyde reductase from two crystal forms. Acta Crystallographica Section D: Biological Crystallography, 1993, 49, 490-496.	2.5	5
27	Aldose and aldehyde reductases from human kidney cortex and medulla. BBA - Proteins and Proteomics, 1993, 1203, 260-266.	2.1	16
28	Diabetic rats show more resistance to neuromuscular blockade induced by aminoglycoside antibiotics. General Pharmacology, 1993, 24, 1415-1418.	0.7	3
29	Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Biochemical Pharmacology, 1993, 46, 21-28.	4.4	38
30	Molecular cloning of testicular 20.alpha.-hydroxysteroid dehydrogenase: Identity with aldose reductase. Biochemistry, 1993, 32, 1401-1406.	2.5	92
31	Hyperglycemic Pseudohypoxia and Diabetic Complications. Diabetes, 1993, 42, 801-813.	0.6	780
32	Levels of expression of hexokinase, aldose reductase and sorbitol dehydrogenase genes in lens of mouse and rat. Current Eye Research, 1993, 12, 323-332.	1.5	15
33	Aldose Reductase Inhibitors: An Update. Annals of Pharmacotherapy, 1993, 27, 751-754.	1.9	40
34	Enzyme immunoassay for erythrocyte aldose reductase. Clinical Chemistry, 1994, 40, 889-894.	3.2	29
35	High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia, 1994, 37, 328-330.	6.3	62
36	Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Documenta Ophthalmologica, 1994, 87, 355-365.	2.2	24
37	Diabetic nephropathy, renal hemodynamics, and aldose reductase inhibitors. Drug Development Research, 1994, 32, 104-116.	2.9	8

#	ARTICLE	IF	CITATIONS
38	Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications. Acta Crystallographica Section D: Biological Crystallography, 1994, 50, 859-868.	2.5	32
39	Polyol and water accumulation in muscle of galactose-fed rats. Biochemical Pharmacology, 1994, 48, 1839-1841.	4.4	2
40	Pharmacokinetics of the Aldose Reductase Inhibitor, Zopolrestat, in Humans. Journal of Clinical Pharmacology, 1994, 34, 760-766.	2.0	18
41	Crystallization and preliminary structure of porcine aldehyde reductase-NADPH binary complex. Acta Crystallographica Section D: Biological Crystallography, 1995, 51, 605-608.	2.5	1
42	Presence of a Closely Related Subgroup in the Aldo-ketoreductase Family of the Mouse. FEBS Journal, 1995, 227, 448-453.	0.2	53
43	The role of polyols in the pathophysiology of hypergalactosemia. European Journal of Pediatrics, 1995, 154, S53-S64.	2.7	61
44	Structure of porcine aldehyde reductase holoenzyme. Nature Structural Biology, 1995, 2, 687-692.	9.7	54
45	The role of aldose reductase in diabetic retinopathy: Prevention and intervention studies. Progress in Retinal and Eye Research, 1995, 14, 593-640.	15.5	17
46	Residues affecting the catalysis and inhibition of rat lens aldose reductase. BBA - Proteins and Proteomics, 1995, 1246, 67-73.	2.1	23
47	Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. BBA - Proteins and Proteomics, 1995, 1249, 117-126.	2.1	163
48	Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes/metabolism Reviews, 1995, 11, 193-225.	0.3	147
49	Acridine orange differential staining of total DNA and RNA in normal and galactosemic lens epithelial cells in culture using flow cytometry. Current Eye Research, 1995, 14, 269-273.	1.5	14
50	Isolation of aldose reductase inhibitors from the flowers of Chrysanthemum boreale. Archives of Pharmacal Research, 1995, 18, 65-68.	6.3	42
51	New approaches for treatment in diabetes: Aldose reductase inhibitors. Biomedicine and Pharmacotherapy, 1995, 49, 232-243.	5.6	55
52	Calcium-mediated disintegrative globulization of isolated ocular lens fibers mimics cataractogenesis. Experimental Eye Research, 1995, 61, 303-310.	2.6	24
53	Characterization of the promoter of the gene for a mouse vas deferens protein related to the aldo-keto reductase superfamily: Effect of steroid hormones and phorbol esters. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 315-325.	2.5	8
54	THE CELLULAR AND MOLECULAR MECHANISMS OF DIABETIC COMPLICATIONS. Endocrinology and Metabolism Clinics of North America, 1996, 25, 255-270.	3.2	251
55	Kinetic and Spectroscopic Evidence for Active Site Inhibition of Human Aldose Reductase. Biochemistry, 1996, 35, 11196-11202.	2.5	39

#	ARTICLE	IF	CITATIONS
56	Synthesis and Aldose Reductase-Inhibitory Activity of Imidazopyrroloquinoline Esters.. Chemical and Pharmaceutical Bulletin, 1996, 44, 1493-1497.	1.3	8
57	Chromosome 7q35 and susceptibility to diabetic microvascular complications. Journal of Diabetes and Its Complications, 1996, 10, 62-67.	2.3	24
58	Hormonal Regulation of Aldose Reductase in Rat Ovary During the Estrous Cycle. FEBS Journal, 1996, 235, 444-448.	0.2	18
59	Crystallization and preliminary X-ray diffraction study of aldehyde reductase from a red yeast, <i>Sporobolomyces salmonicolor</i> . Acta Crystallographica Section D: Biological Crystallography, 1996, 52, 405-406.	2.5	4
60	Cloning, Expression, and Chaperone-like Activity of Human $\alpha$ -Crystallin. Journal of Biological Chemistry, 1996, 271, 31973-31980.	3.4	158
61	Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II—a clinical research center study.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 488-492.	3.6	60
62	Microvasculature in diabetes. Cardiovascular Research, 1996, 32, 764-771.	3.8	30
63	Isolation of the Mouse Aldose Reductase Promoter and Identification of a Tonicity-responsive Element. Journal of Biological Chemistry, 1997, 272, 2615-2619.	3.4	36
64	NAD(P)H-dependent aldose reductase from the xylose-assimilating yeast <i>Candida tenuis</i> : Isolation, characterization and biochemical properties of the enzyme. Biochemical Journal, 1997, 326, 683-692.	3.7	105
65	Inhibition of Aldose Reductase and Sorbitol Accumulation by Astilbin and Taxifolin Dihydroflavonols in <i>Engelhardtia chrysolepis</i> . Bioscience, Biotechnology and Biochemistry, 1997, 61, 651-654.	1.3	58
66	Polyol pathway activation and glutathione redox status in non- $\beta$ -insulin-dependent diabetic patients. Metabolism: Clinical and Experimental, 1997, 46, 1194-1198.	3.4	77
67	Sensitive, selective gas chromatographic-mass spectrometric analysis with trifluoroacetyl derivatives and a stable isotope for studying tissue sorbitol-producing activity. Biomedical Applications, 1997, 688, 1-10.	1.7	5
68	Studies on the inhibitor-binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme-inhibitor ternary complex. , 1997, 29, 186-192.		30
69	Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication. Analytica Chimica Acta, 1998, 365, 285-292.	5.4	22
70	Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis. FEBS Journal, 1998, 256, 310-316.	0.2	20
71	Decreases in Raf-1 levels in galactosaemic lens epithelial cells are partially reversed by myo-inositol. Acta Diabetologica, 1998, 35, 145-149.	2.5	3
72	Improved fluorometric enzymatic sorbitol assay in human blood. Clinica Chimica Acta, 1998, 273, 171-184.	1.1	23
73	An Inhibitor of Aldose Reductase and Sorbitol Accumulation from <i>Anthocephalus chinensis</i> . Planta Medica, 1998, 64, 68-69.	1.3	18

#	ARTICLE	IF	CITATIONS
74	Identification and Characterization of a Novel Human Aldose Reductase-like Gene. <i>Journal of Biological Chemistry</i> , 1998, 273, 11429-11435.	3.4	259
76	Cyclic AMP regulates expression of the gene coding for a mouse vas deferens protein related to the aldo-keto reductase superfamily in human and murine adrenocortical cells. <i>Journal of Endocrinology</i> , 1999, 160, 147-154.	2.6	40
77	Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. <i>Diabetologia</i> , 1999, 42, 1187-1194.	6.3	67
78	Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1999, 237, 758-762.	1.9	7
79	Structural and Kinetic Determinants of Aldehyde Reduction by Aldose Reductase. <i>Biochemistry</i> , 1999, 38, 42-54.	2.5	173
80	Characterization of Genomic Regions Directing the Cell-Specific Expression of the Mouse Aldose Reductase Gene. <i>Biochemical and Biophysical Research Communications</i> , 1999, 255, 759-764.	2.1	9
81	Evaluation of $\pm 1$ $\mu$ M adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. <i>FASEB Journal</i> , 2000, 14, 1548-1558.	0.5	44
82	Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily. , 2000, 38, 41-48.		13
83	Aldose and aldehyde reductases: Correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site. <i>Proteins: Structure, Function and Bioinformatics</i> , 2000, 41, 407-414.	2.6	25
84	Crystallization and aldo-keto reductase activity of Gcy1p from <i>Saccharomyces cerevisiae</i> . <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2000, 56, 763-765.	2.5	14
85	Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. <i>Free Radical Biology and Medicine</i> , 2000, 29, 17-25.	2.9	53
86	Luteinizing Hormone Induces Mouse Vas Deferens Protein Expression in the Murine Ovary. <i>Endocrinology</i> , 2000, 141, 2574-2581.	2.8	28
87	Aldose Reductase-Deficient Mice Develop Nephrogenic Diabetes Insipidus. <i>Molecular and Cellular Biology</i> , 2000, 20, 5840-5846.	2.3	98
88	Cadmium-Dependent Enzyme Activity Alteration Is Not Imputable to Lipid Peroxidation. <i>Archives of Biochemistry and Biophysics</i> , 2000, 383, 288-295.	3.0	54
89	Aldose Reductase does Catalyse the Reduction of Glyceraldehyde Through a Stoichiometric Oxidation of NADPH. <i>Experimental Eye Research</i> , 2000, 71, 515-521.	2.6	31
90	A Potent Aldose Reductase Inhibitor, (2S,4S)-6-Fluoro-2,5-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): Its Absolute Configuration and Interactions with the Aldose Reductase by X-ray Crystallography. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2479-2483.	6.4	67
91	Effects of dietary galactose and fructose on rats fed diets marginal or adequate in copper for 9-21 months. <i>Nutrition Research</i> , 2001, 21, 1078-1087.	2.9	8
92	The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats. <i>Life Sciences</i> , 2001, 68, 1439-1448.	4.3	12

#	ARTICLE	IF	CITATIONS
93	Aldose Reductase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 465-473.	0.5	39
94	Stereospecific Interaction of a Novel Spirosuccinimide Type Aldose Reductase Inhibitor, AS-3201, with Aldose Reductase. Biochemistry, 2001, 40, 8216-8226.	2.5	45
95	Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anti-Cancer Drugs, 2001, 12, 129-132.	1.4	66
96	Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus. Diabetic Medicine, 2001, 18, 906-914.	2.3	45
97	The role of taurine in diabetes and the development of diabetic complications. Diabetes/Metabolism Research and Reviews, 2001, 17, 330-346.	4.0	238
98	Physiological functions and hormonal regulation of mouse vas deferens protein (AKR1B7) in steroidogenic tissues. Chemico-Biological Interactions, 2001, 130-132, 903-917.	4.0	43
99	Functional genomic studies of aldo-“keto reductases. Chemico-Biological Interactions, 2001, 130-132, 673-683.	4.0	31
100	EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radical Biology and Medicine, 2001, 31, 205-216.	2.9	82
101	Comparisons of genomic structures and chromosomal locations of the mouse aldose reductase and aldose reductase-like genes. FEBS Journal, 2001, 259, 726-730.	0.2	11
102	SF-1 (Steroidogenic Factor-1), C/EBP $\beta$ (CCAAT/Enhancer Binding Protein), and Ubiquitous Transcription Factors NF1 (Nuclear Factor 1) and Sp1 (Selective Promoter Factor 1) Are Required for Regulation of the Mouse Aldose Reductase-Like Gene (AKR1B7) Expression in Adrenocortical Cells. Molecular Endocrinology, 2001, 15, 93-111.	3.7	40
103	Substrate-Induced Up-Regulation of Aldose Reductase by Methylglyoxal, a Reactive Oxaldehyde Elevated in Diabetes. Molecular Pharmacology, 2002, 61, 1184-1191.	2.3	67
104	Nitric Oxide Prevents Aldose Reductase Activation and Sorbitol Accumulation During Diabetes. Diabetes, 2002, 51, 3095-3101.	0.6	69
105	Neuropathology and pathogenesis of diabetic autonomic neuropathy. International Review of Neurobiology, 2002, 50, 257-292.	2.0	82
106	Aldose reductase activation is a key component of myocardial response to ischemia. FASEB Journal, 2002, 16, 1-22.	0.5	86
107	The Effects of a Traditional Medicine, Fang-ji-huang-qi-tang (Boi-ogi-to), on Urinary Sugar and Sugar Alcohols in Streptozotocin-induced Diabetic Mice.. Journal of Health Science, 2002, 48, 168-172.	0.9	2
108	A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action:Â 1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol. Journal of Medicinal Chemistry, 2002, 45, 4398-4401.	6.4	19
109	Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochemical and Biophysical Research Communications, 2002, 299, 183-188.	2.1	56
110	Diabetic vascular dysfunction: Links to glucose-induced reductive stress and VEGF. Microscopy Research and Technique, 2002, 57, 390-407.	2.2	56

#	ARTICLE	IF	CITATIONS
111	Structure of human aldose reductase holoenzyme in complex with Statil: An approach to structure-based inhibitor design of the enzyme. <i>Proteins: Structure, Function and Bioinformatics</i> , 2002, 50, 230-238.	2.6	25
112	Structural Biology of the Aldo-Keto Reductase Family of Enzymes: Catalysis and Cofactor Binding. <i>Cell Biochemistry and Biophysics</i> , 2003, 38, 79-101.	1.8	59
113	A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models: 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2-H-pyridazin-3-one. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2283-2286.	6.4	61
114	Aldo- and keto reductases as modulators of stress response. <i>Chemico-Biological Interactions</i> , 2003, 143-144, 325-332.	4.0	21
115	Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. <i>Journal of Neurochemistry</i> , 2003, 87, 497-507.	3.9	66
116	Differential expression of the liver proteome in senescence accelerated mice. <i>Proteomics</i> , 2003, 3, 1883-1894.	2.2	73
117	Contribution of Polyol Pathway to Diabetes-Induced Oxidative Stress. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S233-S236.	6.1	467
118	Polymorphisms of sorbitol dehydrogenase (SDH) gene and susceptibility to diabetic retinopathy. <i>Medical Hypotheses</i> , 2003, 60, 550-551.	1.5	22
119	Biochemical Pathways for Microvascular Complications of Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1858-1866.	1.9	59
120	Possible Involvement of Facilitated Polyol Pathway in Augmentation of Intimal Hyperplasia in Rabbits with Alloxan-induced Hyperglycemia. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 265-275.	1.9	6
121	Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications. <i>Current Medicinal Chemistry</i> , 2003, 10, 1389-1398.	2.4	84
122	Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3010-3019.	3.6	64
123	Effects of Polyol Pathway Hyperactivity on Protein Kinase C Activity, Nociceptive Peptide Expression, and Neuronal Structure in Dorsal Root Ganglia in Diabetic Mice. <i>Diabetes</i> , 2004, 53, 3239-3247.	0.6	60
124	Interaction between the Polyol Pathway and Non-Enzymatic Glycation on Mesangial Cell Gene Expression. <i>Nephron Experimental Nephrology</i> , 2004, 98, e89-e99.	2.2	21
125	Central role for aldose reductase pathway in myocardial ischemic injury. <i>FASEB Journal</i> , 2004, 18, 1192-1199.	0.5	124
126	Corneal Changes After Small-Incision Cataract Surgery in Patients With Diabetes Mellitus. <i>JAMA Ophthalmology</i> , 2004, 122, 966.	2.4	93
127	Aldose Reductase Gene Polymorphisms and Peripheral Nerve Function in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 2021-2026.	8.6	36
128	Pharmacological prevention of diabetic cataract. <i>Journal of Diabetes and Its Complications</i> , 2004, 18, 129-140.	2.3	167



#	ARTICLE	IF	CITATIONS
129	Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 55, 805-813.	2.6	83
130	Potential role for the sorbitol pathway in the meiotic dysfunction exhibited by oocytes from diabetic mice. <i>The Journal of Experimental Zoology</i> , 2004, 301A, 439-448.	1.4	12
131	Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 3797-3806.	3.0	19
132	Diabetic Retinopathy in Children and Adolescents with Type 1 Diabetes. , 2005, 10, 314-328.		1
133	Aldose Reductase and AGE-RAGE Pathways: Key Players in Myocardial Ischemic Injury. <i>Annals of the New York Academy of Sciences</i> , 2005, 1043, 702-709.	3.8	61
134	Angiotensin-Converting Enzymes: Properties and Function. , 2005, , 95-99.		0
135	Fibrates inhibit aldose reductase activity in the forward and reverse reactions. <i>Biochemical Pharmacology</i> , 2005, 70, 1653-1663.	4.4	24
136	Phorbol ester up-regulates aldose reductase expression in A549 cells: a potential role for aldose reductase in cell cycle modulation. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 1146-1155.	5.4	15
137	Aldose Reductase in Diabetic Microvascular Complications. <i>Current Drug Targets</i> , 2005, 6, 475-486.	2.1	128
138	Effects of adenosine and adenosine A2Areceptor agonist on motor nerve conduction velocity and nerve blood flow in experimental diabetic neuropathy. <i>Neurological Research</i> , 2005, 27, 60-66.	1.3	28
139	Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. <i>Brain</i> , 2005, 128, 1026-1037.	7.6	44
140	Ocular Metabolism and Disposition of 4-Hydroxy-2-nonenal. <i>Cutaneous and Ocular Toxicology</i> , 2005, 24, 165-176.	1.3	1
141	Effect of Diabecon on sugar-induced lens opacity in organ culture: mechanism of action. <i>Journal of Ethnopharmacology</i> , 2005, 97, 397-403.	4.1	32
142	Involvement of nuclear factor Î² in up-regulation of aldose reductase gene expression by 12-O-tetradecanoylphorbol-13-acetate in HeLa cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 2297-2309.	2.8	12
143	Factorizing Selectivity Determinants of Inhibitor Binding toward Aldose and Aldehyde Reductases:Â Structural and Thermodynamic Properties of the Aldose Reductase Mutant Leu300Proâ~Fidarestat Complex. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5659-5665.	6.4	54
144	A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:â€ 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6326-6339.	6.4	56
145	Phenolic Marine Natural Products as Aldose Reductase InhibitorsÂ. <i>Journal of Natural Products</i> , 2006, 69, 1485-1487.	3.0	85
146	The role of polyol pathway in high glucose-induced endothelial cell damages. <i>Diabetes Research and Clinical Practice</i> , 2006, 73, 227-234.	2.8	53

#	ARTICLE	IF	CITATIONS
147	On-bead combinatorial techniques for the identification of selective aldose reductase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7728-7735.	3.0	12
148	Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 512-520.	2.2	24
149	Evaluation of aldose reductase inhibition and docking studies of some secondary metabolites, isolated from <i>Origanum vulgare</i> L. ssp. <i>hirtum</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1653-1659.	3.0	33
150	Study of the polyol pathway in the porcine epididymis. <i>Molecular Reproduction and Development</i> , 2006, 73, 859-865.	2.0	20
151	Exploring Structural Requirements for Aldose-Reductase Inhibition by 2,4-Dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl Acetic Acids and 2-Thioxo Analogues: Fujita-Ban and Hansch Approach. <i>Archiv Der Pharmazie</i> , 2006, 339, 327-331.	4.1	6
152	Analysis of glucose metabolism in diabetic rat retinas. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1057-E1067.	3.5	84
153	Regulation of Intracellular Glucose and Polyol Pathway by Thiamine and Benfotiamine in Vascular Cells Cultured in High Glucose. <i>Journal of Biological Chemistry</i> , 2006, 281, 9307-9313.	3.4	124
154	Towards Newer Molecular Targets for Chronic Diabetic Complications. <i>Current Vascular Pharmacology</i> , 2006, 4, 45-57.	1.7	52
155	WY 14,643 inhibits human aldose reductase activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2006, 21, 569-573.	5.2	12
156	Cellular Signaling and Potential New Treatment Targets in Diabetic Retinopathy. <i>Experimental Diabetes Research</i> , 2007, 2007, 1-12.	3.8	74
157	Signal Transduction Therapy of Diabetic Vascular Complication. <i>Current Signal Transduction Therapy</i> , 2007, 2, 91-100.	0.5	5
158	Focus on Molecules: Aldose reductase. <i>Experimental Eye Research</i> , 2007, 85, 739-740.	2.6	48
159	En Route to an Efficient Catalytic Asymmetric Synthesis of AS-3201. <i>Journal of the American Chemical Society</i> , 2007, 129, 11342-11343.	13.7	120
160	Diabetic Retinopathy: From Pathogenesis to Treatment. <i>Experimental Diabetes Research</i> , 2007, 2007, 1-2.	3.8	10
161	The atomic resolution structure of human aldose reductase reveals that rearrangement of a bound ligand allows the opening of the safety-belt loop. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2007, 63, 665-672.	2.5	13
162	Functional studies of aldo-keto reductases in <i>Saccharomyces cerevisiae</i> . <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 321-329.	4.1	60
163	Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 1970-1978.	5.4	56
164	QSAR study of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. <i>Medicinal Chemistry Research</i> , 2008, 17, 258-266.	2.4	8

#	ARTICLE	IF	CITATIONS
165	Polyol pathway and modulation of ischemia-reperfusion injury in Type 2 diabetic BBZ rat hearts. Cardiovascular Diabetology, 2008, 7, 33.	6.8	43
166	Inhibition of aldose reductase from cataracted eye lenses by finger millet ( <i>Eleusine coracana</i> ) polyphenols. Bioorganic and Medicinal Chemistry, 2008, 16, 10085-10090.	3.0	111
167	Disruption of aldo-keto reductase genes leads to elevated markers of oxidative stress and inositol auxotrophy in <i>Saccharomyces cerevisiae</i> . Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 237-245.	4.1	32
168	Association between sorbitol dehydrogenase gene polymorphisms and type 2 diabetic retinopathy. Experimental Eye Research, 2008, 86, 647-652.	2.6	22
169	Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. Physical Therapy, 2008, 88, 1322-1335.	2.4	727
170	Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opinion on Investigational Drugs, 2008, 17, 575-581.	4.1	27
171	Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview. Current Medicinal Chemistry, 2009, 16, 2345-2354.	2.4	62
172	Artificial neural networksâ€based approach to design ARIs using QSAR for diabetes mellitus. Journal of Computational Chemistry, 2009, 30, 2494-2508.	3.3	24
173	Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives. European Journal of Medicinal Chemistry, 2009, 44, 2673-2678.	5.5	73
174	Synthesis and Blood Glucose Lowering Activity of Novel Benzenesulfonyl-Urea Derivatives. Phosphorus, Sulfur and Silicon and the Related Elements, 2009, 184, 2516-2524.	1.6	3
175	Aldo-Keto Reductases in the Eye. Journal of Ophthalmology, 2010, 2010, 1-6.	1.3	22
176	Acetic Acid Derivatives of 3,4-Dihydro-2 <i>H</i> -1,2,4-benzothiadiazine 1,1-Dioxide as a Novel Class of Potent Aldose Reductase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 8330-8344.	6.4	55
177	Polyol pathway and diabetic nephropathy revisited: Early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase. Journal of Diabetes Investigation, 2011, 2, 111-122.	2.4	29
178	Identification, cloning and regulation of cDNA encoding Aldoâ€Keto Reductase 1B7 in the adrenal gland of two saharan rodents <i>Meriones libycus</i> (Libyan jird) and <i>Gerbillus gerbillus</i> (gerbil). General and Comparative Endocrinology, 2011, 174, 292-300.	1.8	0
179	Aldose reductase-mediated induction of epithelium-to-mesenchymal transition (EMT) in lens. Chemico-Biological Interactions, 2011, 191, 351-356.	4.0	35
180	1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase. Bioorganic and Medicinal Chemistry, 2011, 19, 7262-7269.	3.0	43
181	Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold. European Journal of Medicinal Chemistry, 2011, 46, 1536-1544.	5.5	28
182	Inhibitory activities of the edible brown alga <i>Laminaria japonica</i> on glucose-mediated protein damage and rat lens aldose reductase. Fisheries Science, 2011, 77, 1069-1079.	1.6	12

#	ARTICLE	IF	CITATIONS
183	The Role of Cys-298 in Aldose Reductase Function. Journal of Biological Chemistry, 2011, 286, 6336-6344.	3.4	20
184	Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications. Current Medicinal Chemistry, 2012, 19, 3578-3604.	2.4	119
185	Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovascular Research, 2012, 94, 370-378.	3.8	53
186	Synthesis and blood glucose lowering activity of some novel benzenesulfonylurea derivatives substituted with 6-aryl-4,5-dihydropyridazin-3(2H)-ones. Medicinal Chemistry Research, 2012, 21, 4352-4356.	2.4	0
187	Osmotic stress induced oxidative damage: Possible mechanism of cataract formation in diabetes. Journal of Diabetes and Its Complications, 2012, 26, 275-279.	2.3	59
188	The polyol pathway in the bovine oviduct. Molecular Reproduction and Development, 2012, 79, 603-612.	2.0	6
189	Practical Catalytic Asymmetric Synthesis of a Promising Drug Candidate. , 2012, , 219-228.		0
190	An Efficient Synthesis of Quinoxalinone Derivatives as Potent Inhibitors of Aldose Reductase. ChemMedChem, 2012, 7, 823-835.	3.2	68
191	Synthesis and blood glucose lowering activity of some novel benzenesulfonylthiourea derivatives substituted with 6-aryl-4,5-dihydropyridazin-3(2H)-ones. Medicinal Chemistry Research, 2012, 21, 428-436.	2.4	3
192	Discovery of New Selective Human Aldose Reductase Inhibitors through Virtual Screening Multiple Binding Pocket Conformations. Journal of Chemical Information and Modeling, 2013, 53, 2409-2422.	5.4	52
193	Aquaporin 5 knockout mouse lens develops hyperglycemic cataract. Biochemical and Biophysical Research Communications, 2013, 441, 333-338.	2.1	36
194	Antioxidant Potential of Fungal Metabolite Nigerloxin during Eye Lens Abnormalities in Galactose-Fed Rats. Current Eye Research, 2013, 38, 1064-1071.	1.5	7
195	The Boar Reproductive System. , 2013, , 65-107.		5
196	Aldo- keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy. Australasian journal of optometry, The, 2013, 96, 303-309.	1.3	1
197	Stop Crying over Spilled Milk, Thanks to Recent Reports Which Suggest Novel Therapeutic Options for Existing Aldose reductase Inhibitors. Journal of Biomolecular Research & Therapeutics, 2013, 01, .	0.2	0
198	Aldose Reductase: A Multi-disease Target. Current Enzyme Inhibition, 2013, 10, 2-12.	0.4	14
199	Porcine sperm capacitation involves tyrosine phosphorylation and activation of aldose reductase. Reproduction, 2014, 148, 389-401.	2.6	26
200	Association of Diabetic Autonomic Neuropathy with Red Blood Cell Aldose Reductase Activity. Canadian Journal of Diabetes, 2014, 38, 22-25.	0.8	6

#	ARTICLE	IF	CITATIONS
201	Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 669-678.	4.0	67
202	Selective synthesis and comparative activity of olefinic isomers of 1,2-benzothiazine-1,1-dioxide carboxylates as aldose reductase inhibitors. <i>RSC Advances</i> , 2014, 4, 21134.	3.6	10
203	Vicenin 2 isolated from <i>Artemisia capillaris</i> exhibited potent anti-glycation properties. <i>Food and Chemical Toxicology</i> , 2014, 69, 55-62.	3.6	82
204	Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection. <i>European Journal of Medicinal Chemistry</i> , 2014, 76, 352-359.	5.5	28
205	Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs). <i>European Journal of Medicinal Chemistry</i> , 2014, 71, 53-66.	5.5	58
206	Autonomic neuropathy in experimental models of diabetes mellitus. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 126, 579-602.	1.8	16
207	Interaction of aldose reductase and superoxide dismutase activity in liver; influence of vasopressin hormone and its modulators. <i>International Journal of Biomedical Research</i> , 2015, 6, 769.	0.1	0
208	Diabetes and Alzheimer Disease, Two Overlapping Pathologies with the Same Background: Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-14.	4.0	91
209	The inhibitory effect of Isoflavones isolated from <i>Caesalpinia pulcherrima</i> on aldose reductase in STZ induced diabetic rats. <i>Chemico-Biological Interactions</i> , 2015, 237, 18-24.	4.0	20
210	Kinetic and molecular docking studies of loganin and 7-O-galloyl-d-sedoheptulose from <i>Corni Fructus</i> as therapeutic agents for diabetic complications through inhibition of aldose reductase. <i>Archives of Pharmacal Research</i> , 2015, 38, 1090-1098.	6.3	15
211	Chiral resolution, determination of absolute configuration, and biological evaluation of (1,2-benzothiazin-4-yl)acetic acid enantiomers as aldose reductase inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 30, 846-851.	5.2	7
212	Concomitant and discrete expressions of aldose reductase and sorbitol dehydrogenase in the male reproductive tract. <i>Acta Histochemica</i> , 2016, 118, 776-783.	1.8	5
213	In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 502-513.	5.6	33
214	Design and synthesis of chiral 2 H -chromene- N -imidazolo-amino acid conjugates as aldose reductase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 750-762.	5.5	26
215	Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. <i>Cancer &amp; Metabolism</i> , 2016, 4, 11.	5.0	177
216	Characterization of WY 14,643 and its Complex with Aldose Reductase. <i>Scientific Reports</i> , 2016, 6, 34394.	3.3	3
217	Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 731-735.	5.0	2
218	Impact of Diabetic Complications on Balance and Falls: Contribution of the Vestibular System. <i>Physical Therapy</i> , 2016, 96, 400-409.	2.4	69

#	ARTICLE	IF	CITATIONS
219	Synthesis and structure-activity relationship studies of phenolic hydroxyl derivatives based on quinoxalinone as aldose reductase inhibitors with antioxidant activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 887-892.	2.2	20
220	Strategic Incorporation of Fluorine for Drug Discovery and Development. , 2017, , 499-531.		1
221	Antidiabetic and allied biochemical roles of new chromeno-pyrano pyrimidine compounds: synthesis, in vitro and in silico analysis. <i>Medicinal Chemistry Research</i> , 2017, 26, 805-818.	2.4	19
222	Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2324-2330.	2.2	14
223	Phenolic compounds inhibit the aldose reductase enzyme from the sheep kidney. <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, e21936.	3.0	75
224	Influence of aldose reductase on epithelial-to-mesenchymal transition signaling in lens epithelial cells. <i>Chemico-Biological Interactions</i> , 2017, 276, 149-154.	4.0	16
225	Exploration of thioxothiazolidinone-sulfonate conjugates as a new class of aldehyde/aldose reductase inhibitors: A synthetic and computational investigation. <i>Bioorganic Chemistry</i> , 2017, 75, 1-15.	4.1	18
226	Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 34-41.	1.4	10
228	Inhibition of $\alpha$ -glucosidase, $\alpha$ -amylase, and aldose reductase by potato polyphenolic compounds. <i>PLoS ONE</i> , 2018, 13, e0191025.	2.5	162
229	The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 86-97.	6.1	46
230	Flavonoids from Brazilian Cerrado: Biosynthesis, Chemical and Biological Profile. <i>Molecules</i> , 2019, 24, 2891.	3.8	10
231	Exploring antidiabetic potential of adamantyl-thiosemicarbazones via aldose reductase (ALR2) inhibition. <i>Bioorganic Chemistry</i> , 2019, 92, 103244.	4.1	21
232	Polyphenols of marine red macroalga <i>Symphyclocladia latiuscula</i> ameliorate diabetic peripheral neuropathy in experimental animals. <i>Heliyon</i> , 2019, 5, e01781.	3.2	12
233	Understanding Aldose Reductase-Inhibitors interactions with free energy simulation. <i>Journal of Molecular Graphics and Modelling</i> , 2019, 91, 10-21.	2.4	10
234	Aldose reductase inhibitors: 2013-present. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 199-213.	5.0	62
235	Synthesis of new arylsulfonylspiroimidazolidine-2,4-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress. <i>European Journal of Medicinal Chemistry</i> , 2019, 168, 154-175.	5.5	20
236	Identification of quinoxalin-2(1H)-one derivatives as a novel class of multifunctional aldose reductase inhibitors. <i>Future Medicinal Chemistry</i> , 2019, 11, 2989-3004.	2.3	12
237	Structure-Based Drug Design with a Special Emphasis on Herbal Extracts. <i>Challenges and Advances in Computational Chemistry and Physics</i> , 2019, , 271-305.	0.6	0



#	ARTICLE	IF	CITATIONS
238	Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications. <i>Bioorganic Chemistry</i> , 2020, 96, 103570.	4.1	8
239	Methylglyoxal Metabolism and Aging-Related Disease: Moving from Correlation toward Causation. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 81-92.	7.1	71
240	(5-Hydroxy-4-oxo-2-styryl-4H-pyridin-1-yl)-acetic Acid Derivatives as Multifunctional Aldose Reductase Inhibitors. <i>Molecules</i> , 2020, 25, 5135.	3.8	5
241	Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115699.	3.0	10
242	Screening inhibitory effects of selected flavonoids on human recombinant aldose reductase enzyme: <i>in vitro</i> and <i>in silico</i> study. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 1368-1374.	2.1	9
243	Non-Enzymatic Glycation and Formation of Advanced Glycation End-Products Alters the Activity and Related Kinetic Properties of Aldose Reductase. <i>Asian Journal of Chemistry</i> , 2021, 33, 1875-1880.	0.3	0
244	Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy. <i>Toxins</i> , 2021, 13, 560.	3.4	7
245	Curious effects of fluorine on medicinally active compounds. , 2021, , 241-276.		5
246	Localization and Physiological Implication of Aldose Reductase and Sorbitol Dehydrogenase in Reproductive Tracts and Spermatozoa of Male Rats. <i>Journal of Andrology</i> , 2002, 23, 674-684.	2.0	19
247	Mechanisms of Glucose- and Diabetes-Induced Vascular Dysfunction. , 1992, , 107-132.		14
248	Kinetic Alteration of Human Aldose Reductase by Mutagenesis of Cysteine Residues. <i>Advances in Experimental Medicine and Biology</i> , 1993, 328, 289-300.	1.6	4
249	Polymorphisms of the Aldose Reductase Locus (ALR2) and Susceptibility to Diabetic Microvascular Complications. <i>Advances in Experimental Medicine and Biology</i> , 1993, 328, 325-332.	1.6	21
250	Regulation of Aldose Reductase by Aldehydes and Nitric Oxide. <i>Advances in Experimental Medicine and Biology</i> , 1999, 463, 501-507.	1.6	2
251	A Potential Role for Aldose Reductase in Steroid Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 1996, 414, 465-473.	1.6	13
252	High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. <i>Diabetologia</i> , 1994, 37, 328-330.	6.3	6
253	The Lens. , 2011, , 131-163.		10
254	Aldose reductase from human skeletal and heart muscle. Interconvertible forms related by thiol-disulfide exchange.. <i>Journal of Biological Chemistry</i> , 1990, 265, 20982-20987.	3.4	60
255	Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303.. <i>Journal of Biological Chemistry</i> , 1992, 267, 24833-24840.	3.4	103

#	ARTICLE	IF	CITATIONS
256	The crystal structure of the aldose reductase.NADPH binary complex.. Journal of Biological Chemistry, 1992, 267, 24841-24847.	3.4	85
257	Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications.. Journal of Biological Chemistry, 1992, 267, 4364-4369.	3.4	256
258	Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms.. Journal of Biological Chemistry, 1990, 265, 10912-10918.	3.4	59
259	Cloning and expression of human aldose reductase.. Journal of Biological Chemistry, 1990, 265, 9788-9792.	3.4	73
260	Bovine lens aldose reductase. pH-dependence of steady-state kinetic parameters and nucleotide binding.. Journal of Biological Chemistry, 1993, 268, 25494-25499.	3.4	20
261	Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110.. Journal of Biological Chemistry, 1993, 268, 25687-25693.	3.4	109
262	Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor.. Journal of Clinical Investigation, 1997, 99, 2192-2202.	8.2	172
263	Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.. Journal of Clinical Investigation, 1998, 101, 1905-1915.	8.2	377
264	Structural Studies of Aldose Reductase Inhibition. , 2018, , 229-246.		1
265	Effects of Bogijetong-Tang on Diabetic-peripheral Neuropathy Induced by Streptozotocin in the Mouse. Journal of Korean Medicine, 2013, 34, 126-142.	0.4	3
266	Potential of Gentiana lutea for the Treatment of Obesity-associated Diseases. Current Pharmaceutical Design, 2019, 25, 2071-2076.	1.9	5
267	Polyol pathway: A possible mechanism of diabetes complications in the eye. African Vision and Eye Health, 2015, 74, .	0.2	29
268	Neuroprotective efficacy of polyphenols of marine brown macroalga Ecklonia cava in diabetic peripheral neuropathy. Pharmacognosy Magazine, 2019, 15, 468.	0.6	1
269	Aldose Reductase Inhibitory Activity of Butea monosperma for the Management of Diabetic Complications. Pharmacologia, 2015, 6, 355-359.	0.3	1
275	Diabetic Retinopathy: Its Progression and the Effective Treatment to Prevent Blindness. Pharmacologia, 2013, 4, 138-156.	0.3	0
276	Antidiabetic Drugs. , 1990, , 613-623.		0
277	THE CRYSTAL STRUCTURE OF THE ALDOSE REDUCTASE NADPH BINARY COMPLEX. , 1992, 267, 24841-7.		82
278	Roles of Alkaloids from Medicinal Plants in the Management of Diabetes Mellitus. Journal of Chemistry, 2021, 2021, 1-10.	1.9	23



#	ARTICLE	IF	CITATIONS
279	Non-insulin-dependent (type II) diabetes mellitus. Cmaj, 1991, 145, 1571-81.	2.0	3
280	Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. Molecular Vision, 2012, 18, 495-503.	1.1	33
281	Resorcinol Derivatives as Novel Aldose Reductase Inhibitors: In Silico and In Vitro Evaluation. Letters in Drug Design and Discovery, 2022, 19, .	0.7	0
282	Rhodanine scaffold: A review of antidiabetic potential and structureâ€activity relationships (SAR). Medicine in Drug Discovery, 2022, 15, 100131.	4.5	13
284	Algal metabolites: Paving the way towards new generation antidiabetic therapeutics. Algal Research, 2023, 69, 102904.	4.6	4
285	Pantothenate Kinase 4 Governs Lens Epithelial Fibrosis by Negatively Regulating Pyruvate Kinase M2-Related Glycolysis. , 2023, .		0
286	Proteome Changes Induced by Expression of Tumor Suppressor PTEN. Molecules and Cells, 2003, 15, 396-405.	2.6	1
287	Role of Medicinal Plants in the Management of Diabetes Mellitus. , 2023, , 89-103.		0